ArQule, Inc, a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone781-994-0300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$25.76 million
Profitability
Miscellaneous
Employees36
Next Earnings Date10/30/2019 (Confirmed)
OptionableOptionable
ArQule (NASDAQ:ARQL) Frequently Asked Questions
What is ArQule's stock symbol?
ArQule trades on the NASDAQ under the ticker symbol "ARQL."
How were ArQule's earnings last quarter?
ArQule, Inc. (NASDAQ:ARQL) issued its quarterly earnings data on Wednesday, August, 7th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.09) by $0.01. The biotechnology company had revenue of $0.28 million for the quarter, compared to analysts' expectations of $1.43 million. ArQule had a negative net margin of 349.34% and a negative return on equity of 33.45%. During the same quarter in the prior year, the business earned $0.05 EPS. View ArQule's Earnings History.
When is ArQule's next earnings date?
How can I listen to ArQule's earnings call?
ArQule will be holding an earnings conference call on Wednesday, October 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has ArQule issued on next quarter's earnings?
ArQule issued an update on its FY 2019 earnings guidance on Wednesday, August, 7th. The company provided EPS guidance of $-0.37--0.35 for the period, compared to the Thomson Reuters consensus EPS estimate of $-0.38. The company issued revenue guidance of $3-5 million, compared to the consensus revenue estimate of $4.25 million.
What price target have analysts set for ARQL?
7 analysts have issued 12 month target prices for ArQule's stock. Their forecasts range from $11.00 to $16.00. On average, they anticipate ArQule's share price to reach $12.86 in the next twelve months. This suggests a possible upside of 33.2% from the stock's current price. View Analyst Price Targets for ArQule.
What is the consensus analysts' recommendation for ArQule?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ArQule in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ArQule.
What are Wall Street analysts saying about ArQule stock?
Here are some recent quotes from research analysts about ArQule stock:
- 1. According to Zacks Investment Research, "ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche. " (10/16/2019)
- 2. HC Wainwright analysts commented, "We are initiating coverage with a Buy rating and $13 price target. ArQule is a development stage biotech company that is developing four novel oral products, three for oncology indications and one for rare overgrowth diseases. Our price target is based on two of the drugs in the company’s pipeline, specifically ARQ 531 for B-cell malignancies and miransertib for rare tissue overgrowth diseases. Registrational trials for these two drugs are expected to begin in 2H19. We believe these trials will drive more interest in ArQule and push the stock higher. For the other two products, ARQ 751 and derazantinib, we consider them free call options. Management projects cash and marketable securities on the balance sheet will total approximately $160M at the end of 2019, which is forecast to fund operating expenses into 2022. Targeting treatment resistance in B-cell malignancies." (9/16/2019)
Has ArQule been receiving favorable news coverage?
Media headlines about ARQL stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. ArQule earned a coverage optimism score of 0.9 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for ArQule.
Are investors shorting ArQule?
ArQule saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 15,880,000 shares, an increase of 20.1% from the August 30th total of 13,220,000 shares. Based on an average daily trading volume, of 1,960,000 shares, the days-to-cover ratio is presently 8.1 days. Approximately 16.8% of the company's stock are sold short. View ArQule's Current Options Chain.
Who are some of ArQule's key competitors?
Some companies that are related to ArQule include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), EXACT Sciences (EXAS), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS).
What other stocks do shareholders of ArQule own?
Who are ArQule's key executives?
ArQule's management team includes the folowing people:
- Mr. Paolo Pucci, CEO & Director (Age 58)
- Mr. Peter S. Lawrence J.D., Pres, COO, Gen. Counsel & Sec. (Age 56)
- Dr. Brian Schwartz, Chief Medical Officer & Sr. VP (Age 57)
- Mr. Robert J. Weiskopf, CFO, Sr. VP, Principal Accounting Officer & Treasurer (Age 68)
- Dr. Marc Schegerin M.D., CFO, Head of Strategy & Treasurer
Who are ArQule's major shareholders?
ArQule's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Bailard Inc. (0.36%), Rhenman & Partners Asset Management AB (0.17%), Curbstone Financial Management Corp (0.06%), NJ State Employees Deferred Compensation Plan (0.02%) and Meeder Asset Management Inc. (0.01%). Company insiders that own ArQule stock include Paolo Pucci, Patrick J Zenner, Ran Nussbaum, Ronald M Lindsay and Value Fund L P Biotechnology. View Institutional Ownership Trends for ArQule.
Which institutional investors are selling ArQule stock?
ARQL stock was sold by a variety of institutional investors in the last quarter, including NJ State Employees Deferred Compensation Plan and Meeder Asset Management Inc.. View Insider Buying and Selling for ArQule.
Which institutional investors are buying ArQule stock?
ARQL stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Curbstone Financial Management Corp and Bailard Inc.. Company insiders that have bought ArQule stock in the last two years include Paolo Pucci, Patrick J Zenner, Ran Nussbaum and Ronald M Lindsay. View Insider Buying and Selling for ArQule.
How do I buy shares of ArQule?
Shares of ARQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is ArQule's stock price today?
One share of ARQL stock can currently be purchased for approximately $9.65.
How big of a company is ArQule?
ArQule has a market capitalization of $1.16 billion and generates $25.76 million in revenue each year. The biotechnology company earns $-15,480,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. ArQule employs 36 workers across the globe.View Additional Information About ArQule.
What is ArQule's official website?
How can I contact ArQule?
ArQule's mailing address is ONE WALL STREET, BURLINGTON MA, 01803. The biotechnology company can be reached via phone at 781-994-0300 or via email at [email protected]
MarketBeat Community Rating for ArQule (NASDAQ ARQL)
MarketBeat's community ratings are surveys of what our community members think about ArQule and other stocks. Vote "Outperform" if you believe ARQL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARQL will underperform the S&P 500 over the long term. You may vote once every thirty days.
